These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Triglyceride-lowering and anti-inflammatory mechanisms of omega-3 polyunsaturated fatty acids for atherosclerotic cardiovascular risk reduction. Liu QK J Clin Lipidol; 2021; 15(4):556-568. PubMed ID: 34172393 [TBL] [Abstract][Full Text] [Related]
5. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Skulas-Ray AC; Wilson PWF; Harris WS; Brinton EA; Kris-Etherton PM; Richter CK; Jacobson TA; Engler MB; Miller M; Robinson JG; Blum CB; Rodriguez-Leyva D; de Ferranti SD; Welty FK; Circulation; 2019 Sep; 140(12):e673-e691. PubMed ID: 31422671 [TBL] [Abstract][Full Text] [Related]
6. Effect of Omega-3 Fatty Acid Supplementation on Oxylipins in a Routine Clinical Setting. Schmöcker C; Zhang IW; Kiesler S; Kassner U; Ostermann AI; Steinhagen-Thiessen E; Schebb NH; Weylandt KH Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316682 [TBL] [Abstract][Full Text] [Related]
7. Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors. Dawczynski C; Massey KA; Ness C; Kiehntopf M; Stepanow S; Platzer M; Grün M; Nicolaou A; Jahreis G Clin Nutr; 2013 Oct; 32(5):686-96. PubMed ID: 23332800 [TBL] [Abstract][Full Text] [Related]
8. Pleiotropic, cardioprotective effects of omega-3 polyunsaturated fatty acids. Dimitrow PP; Jawien M Mini Rev Med Chem; 2009 Aug; 9(9):1030-9. PubMed ID: 19689400 [TBL] [Abstract][Full Text] [Related]
9. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Ito MK Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750 [TBL] [Abstract][Full Text] [Related]
10. Postprandial lipoproteins and the molecular regulation of vascular homeostasis. Botham KM; Wheeler-Jones CP Prog Lipid Res; 2013 Oct; 52(4):446-64. PubMed ID: 23774609 [TBL] [Abstract][Full Text] [Related]
11. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Toth PP Vasc Health Risk Manag; 2016; 12():171-83. PubMed ID: 27226718 [TBL] [Abstract][Full Text] [Related]
12. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia. Morton AM; Furtado JD; Lee J; Amerine W; Davidson MH; Sacks FM J Clin Lipidol; 2016; 10(6):1442-1451.e4. PubMed ID: 27919362 [TBL] [Abstract][Full Text] [Related]
13. Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. Yates CM; Calder PC; Ed Rainger G Pharmacol Ther; 2014 Mar; 141(3):272-82. PubMed ID: 24201219 [TBL] [Abstract][Full Text] [Related]
14. [Omega-3 Polyunsaturated Fatty Acids in Patients with Hypertriglyceridemias and Atherosclerosis]. Susekov AV Kardiologiia; 2021 Jul; 61(6):88-96. PubMed ID: 34311692 [TBL] [Abstract][Full Text] [Related]
15. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story. Singh S; Arora RR; Singh M; Khosla S Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517 [TBL] [Abstract][Full Text] [Related]